Sepracor faces setbacks with two drugs
This article was originally published in Scrip
Executive Summary
Sepracor has been hit with a double setback as its mid-stage antidepressant SEP-225289 failed a Phase II study, and two paediatric studies of its best-selling sedative Lunesta (eszopiclone) have been placed on hold.